View Older Stories View More Recent Stories

Jan 22, 2020 07:30AM Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.
Jan 22, 2020 07:30AM Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.
Jan 10, 2020 07:32AM Seelos Therapeutics (SEEL) Reports Interim Data from Phase 1 Study of Intransal Racemic Ketamine (SLS-002)
Jan 10, 2020 07:31AM Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)
Jan 10, 2020 07:31AM Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)
Jan 6, 2020 08:12AM Seelos Therapeutics (SEEL) Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program
Jan 6, 2020 08:02AM Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)
Jan 6, 2020 08:02AM Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)
Dec 13, 2019 08:30AM Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference
Dec 13, 2019 08:30AM Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference
Dec 4, 2019 08:01AM Seelos Therapeutics (SEEL) Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
Dec 4, 2019 08:00AM Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 
Dec 4, 2019 08:00AM Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 
Nov 27, 2019 11:03AM Seelos Therapeutics (SEEL) Announces First Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)
Nov 27, 2019 11:00AM Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)
Nov 27, 2019 11:00AM Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)
Nov 20, 2019 09:01AM Seelos Therapeutics (SEEL) Reports Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
Nov 20, 2019 09:00AM Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
Nov 20, 2019 09:00AM Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
Nov 18, 2019 08:05AM Seelos Therapeutics (SEEL) Receives FDA Fast Track Designation for Intranasal Racemic Ketamine
Nov 18, 2019 08:00AM Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)
Nov 18, 2019 08:00AM Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)
Nov 8, 2019 07:00AM Seelos Therapeutics Reports Q3 2019 Pipeline Update
Nov 8, 2019 07:00AM Seelos Therapeutics Reports Q3 2019 Pipeline Update
Nov 1, 2019 10:00AM Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
Nov 1, 2019 10:00AM Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
Oct 21, 2019 09:00AM Seelos Therapeutics Announces Amendment of SLS-002 Agreement
Oct 21, 2019 09:00AM Seelos Therapeutics Announces Amendment of SLS-002 Agreement
Oct 18, 2019 09:00AM Seelos Therapeutics to Participate in Upcoming Investor Conference in November
Oct 18, 2019 09:00AM Seelos Therapeutics to Participate in Upcoming Investor Conference in November
Oct 15, 2019 09:00AM Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
Oct 15, 2019 09:00AM Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
Sep 4, 2019 09:00AM Seelos Therapeutics to Participate in Upcoming Investor Conference in September
Aug 23, 2019 09:12AM Seelos Therapeutics (SEEL) Prices 4.475M Share Registered Direct Offering at $1.50/Sh
Aug 23, 2019 09:00AM Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
Aug 23, 2019 09:00AM Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
Aug 22, 2019 09:00AM Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
Aug 22, 2019 09:00AM Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
Aug 14, 2019 06:00PM Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 14, 2019 06:00PM Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 6, 2019 09:00AM Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
Aug 6, 2019 09:00AM Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
Aug 1, 2019 09:00AM Seelos Therapeutics Reports Q2 2019 Pipeline Update
Aug 1, 2019 09:00AM Seelos Therapeutics Reports Q2 2019 Pipeline Update
Jul 17, 2019 09:10AM Seelos Therapeutics (SEEL) Announces IND Submission for SLS-005
Jul 17, 2019 09:00AM Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
Jul 17, 2019 09:00AM Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
Jul 15, 2019 11:03AM Seelos Therapeutics (SEEL) Announces Receipt of Grant for Funding of SLS-005 Program
Jul 15, 2019 11:00AM Seelos Therapeutics Announces Receipt of a Grant for Funding of SLS-005 Program 
Jul 15, 2019 11:00AM Seelos Therapeutics Announces Receipt of a Grant for Funding of SLS-005 Program 
View More Recent Stories View Older Stories